CureVac GmbH – Product Pipeline Review

Global Markets Direct’s, ‘CureVac GmbH – Product Pipeline Review – 2016’, provides an overview of the CureVac GmbH’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CureVac GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the pipeline therapeutic landscape of CureVac GmbH

The report provides overview of CureVac GmbH including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses CureVac GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features CureVac GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate CureVac GmbH’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for CureVac GmbH

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding CureVac GmbH’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

CureVac GmbH Snapshot 6

CureVac GmbH Overview 6

Key Information 6

Key Facts 6

CureVac GmbH - Research and Development Overview 7

Key Therapeutic Areas 7

CureVac GmbH - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products - Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

CureVac GmbH - Pipeline Products Glance 16

CureVac GmbH - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

CureVac GmbH - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

CureVac GmbH - Drug Profiles 20

CV-9104 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

CV-9103 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

CV-9201 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

CV-8102 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

nadorameran 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Oligonucleotide for Cancer 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Oligonucleotide for Infectious Disease 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Oligonucleotide for Influenza Virus Infection 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Oligonucleotide for respiratory syncytial virus vaccine 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

infectious disease vaccine 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Oligonucleotide for HIV 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Oligonucleotide for Respiratory Syncytial Virus-1 Infection 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Oligonucleotide for Rotavirus Infection 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Oligonucleotide for Undisclosed Indication 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Oligonucleotides for Undisclosed Indication 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Vaccine 1 for oncology 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Vaccine for Oncology 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

CureVac GmbH - Pipeline Analysis 40

CureVac GmbH - Pipeline Products by Target 40

CureVac GmbH - Pipeline Products by Route of Administration 41

CureVac GmbH - Pipeline Products by Molecule Type 42

CureVac GmbH - Recent Pipeline Updates 43

CureVac GmbH - Dormant Projects 46

CureVac GmbH - Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

CureVac GmbH, Key Information 6

CureVac GmbH, Key Facts 6

CureVac GmbH – Pipeline by Indication, 2016 9

CureVac GmbH – Pipeline by Stage of Development, 2016 10

CureVac GmbH – Monotherapy Products in Pipeline, 2016 11

CureVac GmbH – Partnered Products in Pipeline, 2016 12

CureVac GmbH – Partnered Products/ Combination Treatment Modalities, 2016 13

CureVac GmbH – Out-Licensed Products in Pipeline, 2016 14

CureVac GmbH – Out-Licensed Products/ Combination Treatment Modalities, 2016 15

CureVac GmbH – Phase II, 2016 16

CureVac GmbH – Phase I, 2016 17

CureVac GmbH – Preclinical, 2016 18

CureVac GmbH – Discovery, 2016 19

CureVac GmbH – Pipeline by Target, 2016 40

CureVac GmbH – Pipeline by Route of Administration, 2016 41

CureVac GmbH – Pipeline by Molecule Type, 2016 42

CureVac GmbH – Recent Pipeline Updates, 2016 43

CureVac GmbH – Dormant Developmental Projects,2016 46

CureVac GmbH, Other Locations 47

List of Figures

List of Figures

CureVac GmbH – Pipeline by Top 10 Indication, 2016 8

CureVac GmbH – Pipeline by Stage of Development, 2016 10

CureVac GmbH – Monotherapy Products in Pipeline, 2016 11

CureVac GmbH – Out-Licensed Products in Pipeline, 2016 14

CureVac GmbH – Pipeline by Top 10 Target, 2016 40

CureVac GmbH – Pipeline by Route of Administration, 2016 41

CureVac GmbH – Pipeline by Molecule Type, 2016 42


Discounts available for multiple purchases.
+44 20 7947 2745

Saved reports